Close Menu

NEW YORK (GenomeWeb) – Epic Sciences and Genomic Health said today that Medicare contractor Palmetto GBA has issued a draft local coverage determination (LCD) for the Oncotype DX AR-V7 Nucleus Detect test.

The companies said that if finalized, the LCD would extend coverage of the test to 25,000 Medicare patients with advanced prostate cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.